Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The combination of clofarabine and cytarabine is an effective and reasonably well-tolerated
treatment regimen in patients with either relapsed/refractory or newly diagnosed AML. For
this prospective study, we propose the use of clofarabine and cytarabine for second course
induction therapy for patients with persistent AML after treatment with an anthracycline and
cytarabine.